Payment overview · 2025
General Payments
$141.90
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ashley White, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MARANA, AZ · NPI 1841669652
Verified facts
What the public records show
CMS Open Payments records show Ashley White, FNP-C received $141.90 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 87.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.83 | 87.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.07 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 406 | 122 |
| Lisinopril | Lisinopril | 398 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 394 | 126 |
| Losartan Potassium | Losartan Potassium | 336 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 76 |
| Metformin Hcl | Metformin Hcl | 277 | 80 |
| Omeprazole | Omeprazole | 266 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 53 |
| Trazodone Hcl | Trazodone Hcl | 160 | 41 |
| Gabapentin | Gabapentin | 159 | 53 |
| Montelukast Sodium | Montelukast Sodium | 143 | 46 |
| Simvastatin | Simvastatin | 126 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 27 |
| Trulicity | Dulaglutide | 103 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 28 |
| Ibuprofen | Ibuprofen | 93 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 27 |
| Eliquis | Apixaban | 79 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 25 |
| Carvedilol | Carvedilol | 73 | 22 |
| Meloxicam | Meloxicam | 73 | 29 |
| Sertraline Hcl | Sertraline Hcl | 73 | 24 |
| Ozempic | Semaglutide | 67 | 17 |
| Famotidine | Famotidine | 64 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 22 |
| Metformin Hcl Er | Metformin Hcl | 62 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 12 |
| Potassium Chloride | Potassium Chloride | 52 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Glipizide | Glipizide | 50 | 16 |
| Allopurinol | Allopurinol | 47 | 15 |
| Furosemide | Furosemide | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Glipizide Er | Glipizide | 40 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 17 |
| Lovastatin | Lovastatin | 38 | 12 |
| Pregabalin | Pregabalin | 38 | 12 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 35 | 13 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 12 |
| Methocarbamol | Methocarbamol | 33 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Atenolol | Atenolol | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Invokana | Canagliflozin | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 20 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Prednisone | Prednisone | 19 | 17 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Finasteride | Finasteride | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.90 · 2 records | Novo Nordisk Inc | INVEGA SUSTENNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error